加减宣白承气汤抗流感继发肺炎链球菌感染的多组学研究
本研究探讨加减宣白承气汤(XBCQ)通过调节肠-肺轴干预流感病毒(IAV)继发肺炎链球菌(SPN)感染的机制。采用UHPLC-Q-Orbitrap-HRMS分析鉴定60种成分,并建立IAV序贯SPN感染模型,结合16S rRNA测序与代谢组学。结果显示XBCQ降低SPN负荷81.9%,恢复肠道菌群平衡并调节宿主代谢谱。
要点
- XBCQ可降低IAV继发SPN感染模型的SPN负荷81.9%。
- XBCQ恢复肠道菌群平衡并调节宿主代谢谱。
- 微生物群-肠-肺轴是XBCQ发挥保护作用的潜在机制。
核心结论
- XBCQ通过调节微生物群-肠-肺轴预防IAV感染后的SPN重叠感染。
研究设计与样本
- 采用UHPLC-Q-Orbitrap-HRMS对XBCQ进行化学成分分析。
- 建立鼻内接种IAV后序贯SPN的小鼠模型以模拟流感后继发细菌感染。
- 通过病毒/细菌载量、组织病理学、炎症细胞因子和肠道紧密连接蛋白评估疗效。
- 采用16S rRNA测序和代谢组学评估XBCQ干预机制。
主要发现
- UHPLC-Q-Orbitrap-HRMS分析鉴定XBCQ中60种生物活性成分,包括蔗糖、腺苷、鸟苷和桑皮苷A。
- XBCQ使SPN负荷降低81.9%。
- XBCQ恢复肠道菌群平衡并调节宿主代谢谱。
- 相关性分析显示XBCQ改变的微生物群与药效指标及代谢物显著相关。
临床怎么用
- 为XBCQ在流感季节预防细菌性肺炎的临床应用提供潜在科学依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: The Modified Xuanbai Chengqi Decoction (XBCQ), derived from the classical formula "Xuanbai Chengqi Decoction," is a traditional Chinese herbal preparation. Traditional Chinese Medicine (TCM) is crucial for influenza management. Our previous studies have demonstrated the therapeutic effects of XBCQ on pulmonary and intestinal injuries induced by influenza A virus (IAV)/Streptococcus pneumoniae (SPN) co-infection, although the underlying gut-lung axis mechanisms remain to be further elucidated. AIM OF THE STUDY: We hypothesize that XBCQ ameliorates secondary SPN infection by modulating the gut-lung axis through microbiota-metabolite-immune interactions, and we will evaluate its protective effects and mechanistic basis against IAV-induced secondary SPN infection through integrated multi-omics analyses (gut microbiota and metabolomics). MATERIALS AND METHODS: Chemical profiling of XBCQ was performed using ultra-high-performance liquid chromatography coupled with quadrupole-Orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap-HRMS). A sequential infection model was established by intranasal inoculation of IAV followed by SPN to mimic post-influenza secondary bacterial infection. Therapeutic efficacy was validated through quantification of viral/bacterial loads, histopathological analysis, inflammatory cytokines, and intestinal tight junction (TJ) proteins, demonstrating XBCQ's protective effects on both pulmonary and colonic tissues. 16s RNA sequencing and metabonomics were used to evaluate the mechanism of XBCQ intervention in secondary bacterial infection after influenza. RESULTS: UHPLC-Q-Orbitrap-HRMS analysis identified 60 bioactive components in XBCQ, including sucrose, adenosine, guanosine, and mulberroside A. XBCQ reduced SPN burden by 81.9 %, restored gut microbiota balance, and modulated host metabolic profiles. Correlation analysis revealed that the microbiota altered by XBCQ was significantly associated with pharmacodynamic indicators and metabolites, further confirming the reliability of these findings. CONCLUSIONS: XBCQ prevents SPN superinfection following IAV infection by modulating the microbiota-gut-lung axis. These findings provide a potential scientific basis for the clinical application of XBCQ, offering prospective guidance for preventing bacterial pneumonia during influenza seasons.
引用
- Yang J, Shi J, Xu W, et al. Effects of Modified Xuanbai Chengqi Decoction against secondary Streptococcus pneumoniae infection following influenza virus infection: A multi-omics analysis. J Ethnopharmacol. 2025. PMID: 40848905. doi:10.1016/j.jep.2025.120458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。